{
  "id": 19335630,
  "title": "Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn",
  "url": "https://urgent.news/2026/11/10/pharma-firms-focus-on-weight-loss-drugs-could-put-insulin-supply-at-19335630",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T13:00:53.000Z",
  "source": {
    "name": "Guardian Science",
    "slug": "guardian-science",
    "url": "https://www.theguardian.com/business/2026/nov/10/pharma-firms-weight-loss-drugs-insulin-glp-1-ozempic-mounjaro"
  },
  "original_language": "en",
  "account": null,
  "summary": "GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}